Targeting β-catenin to Treat Liver Cancer
Author Information
Author(s): Monga Satdarshan, Lehrich Brandon, Delgado Evan, Yasaka Tyler, Liu Silvia, Cao Catherine, Liu Yuqing, Taheri Mohammad, Guan Xiangnan, Koeppen Hartmut, Singh Sucha, Liu Jia-Jun, Singh-Varma Anya, Krutsenko Yekaterina, Poddar Minakshi, Hitchens T., Foley Lesley, Liang Binyong, Rialdi Alex, Rai Ravi, Patel Panari, Riley Madeline, Bell Aaron, Raeman Reben, Dadali Tulin, Luke Jason, Guccione Ernesto, Ebrahimkhani Mo, Lujambio Amaia, Chen Xin, Maier Martin, Wang Yulei, Broom Wendy, Tao Junyan
Hypothesis
Can targeting β-catenin improve immune responses and tumor reprogramming in hepatocellular carcinoma?
Conclusion
Targeting β-catenin with LNP-CTNNB1 is effective both alone and with immune checkpoint inhibitors in liver cancer patients with specific mutations.
Supporting Evidence
- The study demonstrated significant tumor responses in multiple β-catenin-mutated HCC models.
- Single-cell and spatial transcriptomics revealed reprogramming of CTNNB1-mutated tumors.
- The treatment activated immune regulatory transcription factors and enhanced immune responses.
Takeaway
This study shows that a new treatment can help the immune system fight liver cancer by targeting a specific gene.
Methodology
The study used siRNA encapsulated in lipid nanoparticles to target CTNNB1 in various hepatocellular carcinoma models.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website